Royalty-based biopharma that licenses drug technologies (like Captisol) and collects royalties on partners' approved drugs.
Royalty-based biopharma that licenses drug technologies (like Captisol) and collects royalties on partners' approved drugs.
Earns royalties on partners' drug sales, such as Amgen's Kyprolis, and sells Captisol, an ingredient that makes drugs dissolve, to drugmakers that use it in their products, plus milestone payments when partners hit trial or sales targets. Partners fund most development, so Ligand carries few such costs itself. It spun off its antibody platform, OmniAb, in 2022.
Moat: narrow (IP / patents, scale). A broad portfolio of licensed technology and royalty stakes spreads risk across many partners' drugs.
Headquarters: San Diego, California, United States · Founded: 1987 · Employees: 47
Size Ligand Pharmaceuticals (LGND) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.98B, the 1061st largest of 3,085 United States companies the cockpit tracks. Shares closed at $298.71 on 18 Nov 2026.
Performance Over six months the shares gained 37.2%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 1.0% over the last twelve months (peer median +13.4%); the operating margin is 14.4% (peer median 19.4%).
Valuation It trades at 27.3× forward earnings against a peer median of 19.3× (6th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 58% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +50 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.4 points below its cost of capital (10.1% WACC).
Credit Ligand Pharmaceuticals has 2 bonds outstanding ($1.16B).
Short interest Short interest is 12.3% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $254M | $268M | $167M | $131M | $196M |
| Revenue growth | — | +60% | +27% | -33% | — |
| Gross profit | $207M | $221M | $121M | $88.0M | $119M |
| EBITDA | $73.5M | $80.9M | $60.4M | $47.2M | $56.2M |
| Net income | $51.5M | $124M | -$4.03M | $52.2M | -$33.4M |
| Free cash flow | $90.6M | $48.9M | $94.8M | $45.1M | $120M |
| Capital expenditure | $33.6M | $11.3M | $19.6M | $53.8M | $17.9M |
| Total debt | $1.15B | $451M | $7.11M | $6.17M | $87.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals LGND | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% |
| Royalty Pharma RPRX | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% |
| Innoviva INVA | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LGND | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.5% | +1.2% | 8th lowest of 21 |
| 6-month return | +37.2% | -4.6% | 3rd highest of 20 |
| Distance from 52-week high | -8.6% | -21.9% | 4th highest of 21 |
| Revenue growth (TTM) | +1.0% | +13.4% | lowest of 17 |
| Operating margin | 14.4% | 19.4% | 8th lowest of 18 |
| Forward P/E | 27.3× | 19.3× | 6th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 57.7% | 1.7% | most demanding of 12 |
| Growth delivered (Del g) | +7.5% | +13.3% | 4th lowest of 12 |
| Hurdle (Req g minus delivered) | +50.2 pp | -9.2 pp | most demanding of 12 |
| ROIC minus cost of capital | -8.4 pp | +1.9 pp | 6th lowest of 18 |
| EV / EBITDA | 90.9× | 20.5× | most expensive of 10 |
| Net debt / EBITDA | 9.6× | 0.3× | most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| RemeGen 9995.HK | Hong Kong | $6.07B | -28% | +293% | 61% | 6.3× | -6.8% | +57.9% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
Ligand Pharmaceuticals has 2 bonds outstanding with $1.16B face value.